Juno Therapeutics Company Profile (NASDAQ:JUNO)

About Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:JUNO
  • CUSIP: N/A
  • Web: www.junotherapeutics.com
Capitalization:
  • Market Cap: $4.84589 billion
  • Outstanding Shares: 104,896,000
Average Prices:
  • 50 Day Moving Avg: $43.47
  • 200 Day Moving Avg: $30.97
  • 52 Week Range: $17.52 - $47.03
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.32
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $82.57 million
  • Price / Sales: 55.53
  • Book Value: $8.93 per share
  • Price / Book: 4.89
Profitability:
  • EBITDA: ($288,550,000.00)
  • Net Margins: -354.36%
  • Return on Equity: -27.10%
  • Return on Assets: -20.97%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Misc:
  • Average Volume: 2.60 million shs.
  • Beta: 2.25
  • Short Ratio: 9.97
 

Frequently Asked Questions for Juno Therapeutics (NASDAQ:JUNO)

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics, Inc. (NASDAQ:JUNO) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.96) EPS for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million for the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business's revenue was down 22.8% compared to the same quarter last year. During the same period last year, the company posted ($0.64) EPS. View Juno Therapeutics' Earnings History.

When will Juno Therapeutics make its next earnings announcement?

Juno Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Juno Therapeutics.

Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2017?

15 equities research analysts have issued 1-year price objectives for Juno Therapeutics' shares. Their predictions range from $23.73 to $56.00. On average, they expect Juno Therapeutics' stock price to reach $39.12 in the next year. View Analyst Ratings for Juno Therapeutics.

What are analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:

  • 1. Maxim Group analysts commented, "The past few months have been transformative for the CAR-T space as Novartis’ Kymriah was approved and Gilead’s (GILD – $82.14 – Hold) (formerly Kite’s) axi-cel is likely to be approved in coming weeks. Gilead paid $12B for Kite, and Novartis has set the pricing bar for CAR-T at $475K. CAR-T is likely to be a multi-billion dollar global market opportunity, and that’s just for end- stage blood cancers. The question is if Kite sold for $12B, what’s the potential for Juno? The company is not far behind clinically as JCAR017’s TRANSCEND study will become a registration study and Juno could have its first CAR on the market in 2019." (10/9/2017)
  • 2. According to Zacks Investment Research, "Juno reported wider-than-expected loss in second-quarter 2017 with revenue beating estimates. The company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock. Shares of the company have also underperformed the industry in the last one year. However, the company remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging." (8/28/2017)
  • 3. Cowen and Company analysts commented, "We believe initial data from the Phase I TRANSCEND study indicate that JCAR017 is." (3/30/2017)
  • 4. Wedbush analysts commented, "We see significant value in JUNO's leading array of engineered T-cell technologies that we believe could allow for a differentiated strategy in B-cell malignancies, despite being behind the competition in the race to market. However, competition from other CAR-T products is likely to limit shareholder upside in the near term." (2/1/2017)
  • 5. Leerink Swann analysts commented, "We’re using a 12% discount rate which we think is appropriate as we use probability-weighted sales estimates for the products and believe the CELG (MP) collaboration, equity investment and ex-US opt-in to CD19 programs lower the risk profile relative to Juno’s peers. We assume the CAR-T market will be split among up to 5 competitors long-term, depending on the indication, including JUNO, KITE, NVS, CLLS, BLUE and others, pending further validation of respective products. Based on the complexity of the technology and manufacturing and the lack of regulatory path for generic versions of CAR-T products as a result of patient-specific manufacturing, we believe that CAR-T product sales are sustainable even after the loss of patent exclusivity." (11/28/2016)

Are investors shorting Juno Therapeutics?

Juno Therapeutics saw a drop in short interest during the month of September. As of September 29th, there was short interest totalling 9,481,474 shares, a drop of 29.9% from the September 15th total of 13,519,026 shares. Based on an average trading volume of 2,962,349 shares, the days-to-cover ratio is presently 3.2 days. Approximately 11.2% of the shares of the company are short sold.

Who are some of Juno Therapeutics' key competitors?

Who are Juno Therapeutics' key executives?

Juno Therapeutics' management team includes the folowing people:

  • Howard H. Pien, Independent Chairman of the Board
  • Hans Edgar Bishop, President, Chief Executive Officer, Director
  • Sunil Agarwal M.D., President of Research & Development
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer
  • Bernard J. Cassidy, General Counsel, Secretary
  • Hal V. Barron M.D., Independent Director
  • Jay T. Flatley, Director
  • Richard Klausner M.D., Director

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an initial public offering on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Who owns Juno Therapeutics stock?

Juno Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include CELGENE SWITZERLAND LLC (9.70%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Jay T Flatley, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Institutional Ownership Trends for Juno Therapeutics.

How do I buy Juno Therapeutics stock?

Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juno Therapeutics' stock price today?

One share of Juno Therapeutics stock can currently be purchased for approximately $43.71.


MarketBeat Community Rating for Juno Therapeutics (NASDAQ JUNO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Juno Therapeutics (NASDAQ:JUNO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $39.12 (10.49% downside)
Consensus Price Target History for Juno Therapeutics (NASDAQ:JUNO)
Price Target History for Juno Therapeutics (NASDAQ:JUNO)
Analysts' Ratings History for Juno Therapeutics (NASDAQ:JUNO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Maxim GroupReiterated RatingBuy -> Buy$34.00 -> $56.00N/AView Rating Details
10/6/2017Goldman Sachs Group IncReiterated RatingNeutral -> Neutral$44.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $43.00N/AView Rating Details
9/6/2017Barclays PLCInitiated CoverageOverweight$55.00MediumView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform -> Outperform$35.00 -> $54.00LowView Rating Details
8/31/2017Standpoint ResearchReiterated RatingBuy -> ReduceMediumView Rating Details
8/29/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$45.00HighView Rating Details
8/29/2017WedbushUpgradeNeutral -> Outperform$42.00 -> $42.00HighView Rating Details
8/28/2017BTIG ResearchUpgradeSell -> NeutralHighView Rating Details
6/20/2017Leerink SwannReiterated RatingOutperform$34.00LowView Rating Details
5/18/2017FBR & CoReiterated RatingHoldMediumView Rating Details
4/4/2017Citigroup Inc.Lower Price TargetBuy$34.00 -> $30.00LowView Rating Details
3/30/2017Cowen and CompanyReiterated RatingBuy$41.00 -> $36.00LowView Rating Details
3/3/2017J P Morgan Chase & CoReiterated RatingNeutral$34.00 -> $31.00N/AView Rating Details
11/25/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$48.00 -> $25.00N/AView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyN/AView Rating Details
2/17/2016GuggenheimUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Juno Therapeutics (NASDAQ:JUNO)
Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Earnings History by Quarter for Juno Therapeutics (NASDAQ JUNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.80)N/AView Earnings Details
8/3/2017Q2 2017($0.72)($0.96)$15.59 million$21.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.70)($0.71)$16.00 million$19.30 millionViewListenView Earnings Details
3/1/2017Q416($0.61)($0.65)$14.57 million$21.15 millionViewListenView Earnings Details
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.54)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.73)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Juno Therapeutics (NASDAQ:JUNO)
2017 EPS Consensus Estimate: ($3.20)
2018 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.70)($0.70)($0.70)
Q2 20171($0.74)($0.74)($0.74)
Q3 20172($0.96)($0.76)($0.86)
Q4 20172($0.98)($0.81)($0.90)
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($0.97)($0.97)($0.97)
Q3 20181($0.99)($0.99)($0.99)
Q4 20181($1.09)($1.09)($1.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Juno Therapeutics (NASDAQ:JUNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Juno Therapeutics (NASDAQ:JUNO)
Insider Ownership Percentage: 15.26%
Institutional Ownership Percentage: 67.38%
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Sunil AgarwalInsiderSell7,285$44.76$326,076.60View SEC Filing  
9/14/2017Bernard J CassidyGeneral CounselSell28,000$44.92$1,257,760.00View SEC Filing  
9/13/2017Robert AzelbyEVPSell12,850$44.95$577,607.50View SEC Filing  
9/7/2017Richard KlausnerDirectorSell12,000$42.66$511,920.00View SEC Filing  
8/29/2017Robert AzelbyEVPSell12,869$39.95$514,116.55View SEC Filing  
8/7/2017Richard KlausnerDirectorSell12,000$30.34$364,080.00View SEC Filing  
7/13/2017Douglas K BrattonMajor ShareholderSell8,000,000$27.00$216,000,000.00View SEC Filing  
7/7/2017Richard KlausnerDirectorSell24,000$29.39$705,360.00View SEC Filing  
7/3/2017Steve HarrCFOSell8,750$30.00$262,500.00View SEC Filing  
6/27/2017Steve HarrCFOSell8,750$30.00$262,500.00View SEC Filing  
6/20/2017Anthony B EvninDirectorBuy9,000$24.40$219,600.00View SEC Filing  
5/26/2017Jay T FlatleyDirectorBuy20,000$24.76$495,200.00View SEC Filing  
3/10/2017Anthony B EvninDirectorBuy8,000$22.11$176,880.00View SEC Filing  
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.94View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.00View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.80View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.52View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.00View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.48View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.00View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.00View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.00View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.00View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.00View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.00View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.00View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.00View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.00View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.50View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Juno Therapeutics (NASDAQ:JUNO)
Latest Headlines for Juno Therapeutics (NASDAQ:JUNO)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Anticipate Juno Therapeutics, Inc. (JUNO) Will Post Quarterly Sales of $19.16 Million
www.americanbankingnews.com - October 21 at 1:08 AM
prnewswire.com logoTrianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform - PR Newswire (press release)
www.prnewswire.com - October 18 at 3:33 PM
streetinsider.com logoJuno Therapeutics (JUNO), Trianni Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform - StreetInsider.com
www.streetinsider.com - October 18 at 3:33 PM
finance.yahoo.com logoTrianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform
finance.yahoo.com - October 18 at 3:33 PM
americanbankingnews.com logoContrasting Juno Therapeutics (JUNO) and Its Peers
www.americanbankingnews.com - October 14 at 2:18 AM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Short Interest Update
www.americanbankingnews.com - October 13 at 1:58 AM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Price Target Increased to $56.00 by Analysts at Maxim Group
www.americanbankingnews.com - October 9 at 8:16 AM
streetinsider.com logoForm 4 Juno Therapeutics, Inc. For: Oct 05 Filed by: EVNIN ANTHONY B - StreetInsider.com
www.streetinsider.com - October 7 at 11:51 PM
fool.com logoHere's Why Juno Therapeutics Stock May Still Be Worth Buying - Motley Fool
www.fool.com - October 7 at 11:51 PM
streetinsider.com logoForm 4 Juno Therapeutics, Inc. For: Oct 05 Filed by: EVNIN ANTHONY B
www.streetinsider.com - October 7 at 6:51 PM
americanbankingnews.com logoMorgan Stanley Reiterates "Equal Weight" Rating for Juno Therapeutics, Inc. (JUNO)
www.americanbankingnews.com - October 7 at 12:22 PM
streetinsider.com logoForm 4 Juno Therapeutics, Inc. For: Oct 05 Filed by: PIEN HOWARD H
www.streetinsider.com - October 7 at 5:54 AM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Reiterates "Neutral" Rating for Juno Therapeutics, Inc. (JUNO)
www.americanbankingnews.com - October 6 at 8:34 PM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Insider Sells $326,076.60 in Stock
www.americanbankingnews.com - October 4 at 10:22 PM
americanbankingnews.com logo$19.16 Million in Sales Expected for Juno Therapeutics, Inc. (JUNO) This Quarter
www.americanbankingnews.com - October 3 at 10:02 AM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 30 at 7:08 AM
investorplace.com logoJuno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish - Investorplace.com
investorplace.com - September 27 at 10:27 AM
investorplace.com logoJuno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish
investorplace.com - September 27 at 7:30 AM
finance.yahoo.com logoETFs with exposure to Juno Therapeutics, Inc. : September 25, 2017
finance.yahoo.com - September 25 at 6:44 PM
nasdaq.com logoJuno Tenders $250M Follow-on Public Offering of Common Stock - Nasdaq
www.nasdaq.com - September 23 at 7:38 PM
businesswire.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of ... - Business Wire (press release)
www.businesswire.com - September 23 at 7:38 PM
investorplace.com logoJuno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy? - Investorplace.com
investorplace.com - September 22 at 7:08 PM
finance.yahoo.com logoOddly, Juno Therapeutics Is Jumping 11.3% Today
finance.yahoo.com - September 22 at 7:08 PM
finance.yahoo.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of Shareholders
finance.yahoo.com - September 22 at 7:08 PM
investorplace.com logoJuno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?
investorplace.com - September 22 at 7:18 AM
businesswire.com logoJuno Therapeutics Launches Follow-on Offering - Business Wire (press release)
www.businesswire.com - September 21 at 8:41 AM
rttnews.com logoJuno Therapeutics Inc. (JUNO) Is Falling After Offering Announcement
www.rttnews.com - September 21 at 12:26 AM
finance.yahoo.com logoJuno Therapeutics Launches Follow-on Offering
finance.yahoo.com - September 21 at 12:26 AM
finance.yahoo.com logoJuno Therapeutics to launch $225 million follow-on offering
finance.yahoo.com - September 21 at 12:26 AM
globenewswire.com logoStull, Stull & Brody Announces Lawsuit Against Certain Officers and Directors of Juno Therapeutics, Inc. (NASDAQ ... - GlobeNewswire (press release)
globenewswire.com - September 19 at 9:01 PM
investorplace.com logoYes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade - Investorplace.com
investorplace.com - September 19 at 9:01 PM
investorplace.com logoYes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade
investorplace.com - September 19 at 7:30 AM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:02 AM
americanbankingnews.com logoInsider Selling: Juno Therapeutics, Inc. (JUNO) General Counsel Sells 28,000 Shares of Stock
www.americanbankingnews.com - September 14 at 10:52 PM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) EVP Sells $577,607.50 in Stock
www.americanbankingnews.com - September 14 at 10:52 PM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Coverage Initiated at Barclays PLC
www.americanbankingnews.com - September 10 at 5:16 PM
fool.com logoCAR-T Mania: Could Juno Therapeutics Get Acquired Next? - Motley Fool
www.fool.com - September 10 at 5:40 AM
americanbankingnews.com logoInsider Selling: Juno Therapeutics, Inc. (JUNO) Director Sells 12,000 Shares of Stock
www.americanbankingnews.com - September 8 at 10:08 PM
bizjournals.com logoTechnical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma
www.bizjournals.com - September 7 at 10:43 PM
nasdaq.com logoNotable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD - Nasdaq.com - Nasdaq
www.nasdaq.com - September 7 at 1:13 AM
fool.com logoWhy Juno Therapeutics Shares Vaulted 46% Higher in August - Motley Fool
www.fool.com - September 7 at 1:13 AM
americanbankingnews.com logoWells Fargo & Company Reaffirms "Outperform" Rating for Juno Therapeutics, Inc. (JUNO)
www.americanbankingnews.com - September 5 at 11:36 PM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 6:50 AM
americanbankingnews.com logoJuno Therapeutics Sees Unusually High Options Volume (JUNO)
www.americanbankingnews.com - September 1 at 2:56 AM
americanbankingnews.com logoInsider Selling: Juno Therapeutics, Inc. (JUNO) EVP Sells 12,869 Shares of Stock
www.americanbankingnews.com - August 31 at 10:22 PM
americanbankingnews.com logoJuno Therapeutics, Inc. (JUNO) Receives Reduce Rating from Standpoint Research
www.americanbankingnews.com - August 31 at 10:46 AM
americanbankingnews.com logoWedbush Equities Analysts Boost Earnings Estimates for Juno Therapeutics, Inc. (JUNO)
www.americanbankingnews.com - August 31 at 7:58 AM
investopedia.com logoJuno Stock Continues Breakout After Gilead Buys Kite
www.investopedia.com - August 31 at 6:36 AM
nasdaq.com logoJUNO Crosses Above Average Analyst Target
www.nasdaq.com - August 30 at 5:13 AM
finance.yahoo.com logoJuno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal
finance.yahoo.com - August 30 at 5:13 AM

Social

Chart

Juno Therapeutics (JUNO) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.